About this trial
About 179 million people die from cardiovascular disease each year, accounting for approximately 31% of global deaths. It is expected that this number will exceed 236 million by 2030, and the economic burden caused by this disease is increasing year by year.At present, the number of people suffering from cardiovascular diseases in China is as high as 330 million, and the mortality rate accounts for more than 40% of the total deaths caused by diseases, and is in a continuous upward trend.Long term dyslipidemia will increase the incidence rate and mortality of atherosclerotic diseases.Tibetan tea contains catechins, caffeine, amino acids, vitamins, and various mineral components, which have significant effects in reducing cholesterol, improving carbohydrate metabolism, lowering blood sugar, losing weight, softening human blood vessels, and other aspects.At present, there are no research reports on the lipid-lowering effect of Mongolian Gongzi Tibetan Tea Special Drink, and most studies on the lipid-lowering effect of Tibetan Tea are animal experiments or clinical observational studies. Therefore, this study intends to use a randomized controlled trial to explore the lipid-lowering efficacy and safety of Mongolian Gongzi Tibetan Tea Special Drink in patients with hyperlipidemia.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Meets the diagnostic criteria for hyperlipidemia: total cholesterol (TC) ≥ 6.20mmol/L, triglycerides (TG) ≥ 2.30 mmol/L. If one of the above blood lipid indicators is abnormal, it can be included in this study;
Age ≥ 18 years old, gender not limited;
The patient is willing to follow the research protocol and sign an informed consent form.
Disqualifiers
Atherosclerotic cardiovascular disease (ASCVD) patients;
Diabetes patients;
Severe hypercholesterolemia (TC>8 mmol/L or LDL-C ≥ 4.9 mmol/L) or severe hypertriglyceridemia (TG ≥ 5.6 mmol/L);
Secondary hyperlipidemia;
Trial design
Parallel
Treatments tested in this trial
Menggongzi Tibetan Tea Special Drink
Other interventionMenggongzi Tibetan Tea Special Drink (50ml/time, taken after breakfast and lunch)+Low fat diet
Atorvastatin Calcium 20Mg Tab
DrugAtorvastatin Calcium Tablets (20mg, qn)+Low Fat Diet
Low fat diet
Other interventionLow fat diet
Treatment groups
Trial outcomes
Primary outcomes
TC
Comparison of TC levels between Tibetan tea and a simple low-fat diet compared to baseline
TG
Comparison of TG levels between Tibetan tea and atorvastatin compared to baseline
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: